CN-121971453-A - Application of diosgenin in preparing medicament for preventing or treating addiction to flumidone

Abstract

The invention discloses a novel medical application of diosgenin, and relates to an application of diosgenin in preparing a drug for preventing and/or treating addiction to flumidone. The invention evaluates the influence of diosgenin on the core behavioral indicators of the addiction of the flumidone through an animal model, wherein the influence comprises the psychomotor hyperfunction induced by the flumidone and the foraging behavior based on the condition position preference. The result shows that the diosgenin can obviously inhibit the increase of psychomotor activity caused by the flumidone and effectively reverse the foraging behavior favored by the conditional position. The diosgenin can relieve the positive strengthening and psychomotor stimulation effects of the flumidone, so that the dependence and craving on the flumidone are effectively weakened, and the flumidone can be used for preventing and treating the addiction of the flumidone. The invention provides definite direction and experimental basis for developing the anti-fluoraminone addiction medicine with diosgenin as an active ingredient, and has good clinical application prospect.

Inventors

• XIE YUAN
• WANG JIAYING
• LIU MIN
• WANG GUANGJI

Assignees

• 中国药科大学

Dates

Publication Date

20260505

Application Date

20260228

Claims (7)

1. 1. The application of diosgenin in preparing medicine for preventing or treating addiction to flumidone is provided. The diosgenin compound is characterized by comprising the following structure: 。
2. 2. the use according to claim 1, wherein the medicament comprises diosgenin and pharmaceutically acceptable excipients.
3. 3. The use according to claim 2, wherein the pharmaceutically acceptable excipients comprise one or more of fillers, diluents, binders, permeation enhancers, absorption enhancers, surfactants, pH-adjusting agents, antioxidants, stabilizers, chelating agents, propellants, porogens, film formers, solvents, co-solvents, flavoring agents, sweeteners and pigments.
4. 4. The use according to claim 3, wherein the diosgenin is used in combination with other active ingredients having a therapeutic or adjuvant therapy for withdrawal from flumidone addiction.
5. 5. The use according to claim 1, wherein the pharmaceutically effective dose of diosgenin is 40mg/kg to 80mg/kg.
6. 6. The use according to claim 1, wherein the pharmaceutical dosage form is a pharmaceutically acceptable dosage form, including a dosage form for parenteral administration and a dosage form for parenteral administration.
7. 7. The use according to claim 6, wherein the dosage form for parenteral administration comprises one or more of tablets, capsules, soft capsules, liquid capsules, granules, drop pills, syrups, dry suspensions, oral solutions, oral suspensions, orally disintegrating tablets, orally fast dissolving films, sustained release tablets, controlled release tablets, sustained release capsules, controlled release capsules, enteric tablets and enteric capsules, and the dosage form for parenteral administration comprises one or more of water injection, freeze-dried powder injection, sterile powder injection, infusion, eye drops, nasal spray, pulmonary inhalants, transdermal patches, liniments, ointments, creams, suppositories, subcutaneous implants, long-acting injections and microneedle preparations.

Description

Application of diosgenin in preparing medicament for preventing or treating addiction to flumidone Technical Field The invention belongs to the field of biological medicine, and particularly relates to a new application of diosgenin in preparing a medicine for preventing and/or treating flumidone addiction withdrawal. Background Drug addiction, or substance use disorder, is a chronic, recurrent disease affecting brain and behavior, resulting in uncontrollable, compulsive craving and use of legal and illegal substances. Fluoroaminoketone (2-Fluorodeschloroketamine, 2-FDCK), having the molecular formula C13H16FNO, is a structural analogue of ketamine, the chlorine atom on the benzene ring of which is replaced by fluorine atom, was first synthesized by Wang Shiyu et al in 1987. CAS 111982-50-4, the structure is as follows:。 the fluoroaminone belongs to aryl cyclohexylamine compounds. According to user feedback from network platforms such as Erowid, bluelight and TRIPPYWIKI, the risk of fluoraminoketone is significantly higher than that of ketamine, at the same dose, which can induce a stronger, more durable separation illusion. The diosgenin is an important natural steroidal sapogenin, and researches prove that the diosgenin has multi-target therapeutic potential and has wide pharmacological activity in various disease models of anti-tumor, anti-inflammatory, blood sugar reducing, anxiolytic, antidepressant, cardiovascular function improving, immunity regulating and the like. However, there is no report about the prevention and/or treatment of withdrawal from the addiction to flumidone. Disclosure of Invention Aiming at the problem of lack of safe and efficient treatment medicine for contraband addiction, the invention provides the application of the traditional Chinese medicine monomer diosgenin in preparing the medicine for preventing and/or treating the flumidone addiction withdrawal for the first time, and promotes the development of related medicines. The invention provides an application of diosgenin in preparing a drug for preventing and/or treating addiction to fluoraminoketone, wherein the structure of the diosgenin compound is as follows: 。 The invention relates to a drug for stopping addiction of flumidone, which is prepared by taking diosgenin as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients. Further, the drug for withdrawal from addiction to flumidone may or may not include other active ingredients. As a specific embodiment, the fluazinone drug of the present invention has diosgenin as the sole active ingredient. As a specific embodiment, the fluazinone drug of the invention can be used in combination with other active ingredients having therapeutic or adjunctive therapeutic action. Pharmaceutically acceptable excipients, including but not limited to fillers, diluents, binders, excipients, permeation enhancers, absorption enhancers, surfactants, pH-adjusting agents, antioxidants, stabilizers, chelating agents, propellants, porogens, film formers, solvents, co-solvents, flavoring agents, sweeteners, colors, and the like, which are commonly used in pharmacy. Preferably, the effective dosage of the diosgenin is 40 mg/kg-80 mg/kg, and the optimal dosage is 40mg/kg. The flumidone addiction stopping medicine can be any pharmaceutically acceptable dosage form, including but not limited to dosage forms for gastrointestinal tract administration and parenteral tract administration, wherein the dosage forms for gastrointestinal tract administration can be tablets, capsules, soft capsules, liquid capsules, granules, dripping pills, syrups, dry suspensions, oral solutions, oral suspensions, orally disintegrating tablets, oral instant films, sustained release tablets, controlled release tablets, sustained release capsules, controlled release capsules, enteric-coated tablets and enteric-coated capsules, and the dosage forms for parenteral tract administration can be water injection, freeze-dried powder injection, sterile powder injection, transfusion, eye drops, nasal spray, pulmonary inhalants, transdermal patches, liniments, ointments, creams, suppositories, subcutaneous implants, long-acting injections and microneedle preparations. The present invention is not limited to the above dosage forms, and any dosage form that is medically approved is within the scope of the present invention. In the present invention, addiction refers to a chronic recurrent brain disease, which is characterized by compulsive medication, foraging, re-inhalation and increased behavioral activity under the condition that adverse consequences are known to occur. In animal models, it appears as a Conditional Position Preference (CPP) model. The invention has the beneficial effects that through observing the condition position preference behavior of mice, the diosgenin has a therapeutic effect on the withdrawal response of the fluazinone addiction, and specifically: 1) Aiming at t